Lead Investigator: Guru Sonpavde, Dana Farber Cancer Institute
Title of Proposal Research: Mathematical prognostic model utilizing multi-platform dynamics in patients with metastatic urothelial carcinoma receiving post-platinum PD1/L1 inhibitors
Vivli Data Request: 7601
Funding Source: None
Potential Conflicts of Interest: My conflicts and Disclosures in the past 36 months are as follows, but do not impact my ability to conduct this project in my judgment: Advisory Board: BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly/Loxo Oncology, Infinity Pharmaceuticals. Research Support to Institution: Sanofi, Astrazeneca, Gilead, QED, Predicine, BMS, EMD Serono. Steering committee of studies: BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics (all unpaid), and Astrazeneca, EMD Serono, Debiopharm (paid). Data safety monitoring committee: Mereo. Employment: Spouse employed by Myriad. Travel costs: BMS, Astrazeneca. Writing/Editor fees: Uptodate, Editor of Elsevier Practice Update Bladder Cancer Center of Excellence. Speaking fees: Physicians Education Resource (PER), Onclive, Research to Practice, Medscape, Cancer Network, Masters Lecture Series (MLS). We will manage the potential Conflicts of Interest (COI) in our proposal. The organisations/individuals involved in funding other projects above are not connected to this specific project and will have no involvement in research development, analysis or interpretation in this project. All the potential conflicts are disclosed to the institution and on publications and presentations as required by institutions.
Summary of the Proposed Research:
Bladder cancer affects ~80,000 individuals every year in the USA. Approximately 1 in 4 patients have aggressive cancer that is not always curable. Patients with bladder cancer that has spread outside the bladder (metastatic or stage-4 bladder cancer) receiving immunotherapy have different responses and outcomes. Only 1 in 5 patients have shrinkage of the cancer, while the remaining have no change or growth of cancer on immunotherapy. Patients who receive chemotherapy typically have more brief benefits compared to immunotherapy. A large number of patients are not fit for further treatment when the cancer grows. Hence, it would be useful to be able to discriminate at an early time point between those who have growth and those who have benefit for a long time on immunotherapy. A user-friendly model that discriminates outcomes of these patients with high accuracy can be exploited to improve therapeutic strategies. For those predicted to have poor long-term outcomes on immunotherapy, earlier switch to other new treatments or intensification of therapy by combinations of new agents with immunotherapy may improve outcomes. This study proposes to construct a mathematical model utilizing early changes in readily available clinical (e.g. organs of spread of cancer, fitness of patient, age, weight, gender, side effects) and laboratory variables (blood cell counts, blood albumin, cancer size measurement). We will analyze 931 patients with metastatic bladder cancer who were enrolled in the IMvigor211 trial, which was a phase 3 clinical trial comparing atezolizumab immunotherapy versus chemotherapy in those who had cancer growing after previous chemotherapy.
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Data Contributor: Roche
Study ID: NCT02302807
Sponsor ID: GO29294